Pompe's disease - RePub - Erasmus Universiteit Rotterdam

Chapter 1
47. Rudolph, C., et al., Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring
plasmid DNA into cells. J Biol Chem, 2003. 278(13): p. 11411-8.
48. Hug, G., W.K. Schubert, and G. Chuck. Type II glycogenosis: Treatment with extract of Aspergillus Niger. Abstr.
in Clin Res. 1968.
49. Baudhuin, P., H.G. Hers, and H. Loeb, An electron microscopic and biochemical study of type II glycogenosis.
Lab. Invest., 1964. 13: p. 1139-1152.
50. Hug, G. and W.K. Schubert, Lysosomes in type II glycogenosis. Changes during administration of extract from
Aspergillus niger. J Cell Biol, 1967. 35(1): p. C1-6.
51. de Barsy, T., et al., Enzyme replacement in Pompe disease: an attempt with purifi ed human acid alphaglucosidase.
Birth Defects Orig Artic Ser, 1973. 9(2): p. 184-90.
52. Pentchev, P.G., Enzyme replacement therapy in Gaucher’s and Fabry’s disease. Ann Clin Lab Sci, 1977. 7(3):
p. 251-3.
53. Godel, V., Visual functions in Tay Sachs diseased patients following enzyme replacement therapy. Metabolic
Ophtalmology, 1978. 2: p. 27-32.
54. Greene, H.L., G. Hug, and W.K. Schubert, Metachromatic leukodystrophy. Treatment with arylsulfatase-A. Arch
Neurol, 1969. 20(2): p. 147-53.
55. Stahl, P.D., et al., Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal
glycosidases by alveolar macrophages. Proc Natl Acad Sci U S A, 1978. 75(3): p. 1399-403.
56. Sando, G.N. and E.F. Neufeld, Recognition and receptor-mediated uptake of a lysosomal enzyme, α-Liduronidase,
by cultured human fi broblasts. Cell, 1977. 12: p. 619-627.
57. Kornfeld, S., et al., Steps in the phosphorylation of the high mannose oligosaccharides of lysosomal enzymes.
Ciba Found Symp, 1982. 92: p. 138-56.
58. Barton, N.W., et al., Replacement therapy for inherited enzyme defi ciency. Macrophage-targeted
glucocerebrosidase for Gaucher’s disease. N. Engl. J. Med., 1991. 324(21): p. 1464-1470.
59. Barton, N.W., et al., Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with
Gaucher disease. Proc. Natl. Acad. Sci. USA, 1990. 87: p. 1913-1916.
60. Kakkis, E.D., et al., Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab, 2001.
72(3): p. 199-208.
61. Miranda, S.R., et al., Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice
leads to visceral, but not neurological, correction of the pathophysiology. Faseb J, 2000. 14(13): p. 1988-95.
62. Hirschhorn, R. and A.J.J. Reuser, Glycogen Storage Disease type II; acid α-Glucosidase (Acid Maltase)
defi ciency, in The Metabolic and Molecular Bases of Inhertited Disease, D.V. M.D., Editor. 2001, Mc Graw-Hill:
New York. p. 3389-3420.
63. Pompe, J.C., Over idiopathische hypertrofi e van het hart. Ned Tijdsch Geneesk, 1932. 76: p. 304-311.
64. Mekanik, G., R.L. Smith, and R.M. MacLeod, Enzyme patterns in glycogen storage disease type II (Pompe’s
disease). Metabolism, 1966. 15(7): p. 641-8.
65. Smith, J., H. Zellweger, and A.K. Afi fi , Muscular form of glycogenosis, type II (Pompe). Neurology, 1967. 17(6):
p. 537-549.
66. Swaiman, K.F., W.R. Kennedy, and H.S. Sauls, Late infantile acid maltase defi ciency. Arch Neurol, 1968. 18(6):
p. 642-648.
67. Hudgson, P. and J.J. Fulthorpe, The pathology of type II skeletal muscle glycogenosis. A light and electronmicroscopic
study. J Pathol, 1975. 116(3): p. 139-47.
68. Engel, A.G., Acid maltase defi ciency in adults: studies in four cases of a syndrome which may mimic muscular
dystrophy or other myopathies. Brain, 1970. 93(3): p. 599-616.
69. Gussenhoven, W.J., et al., Echocardiographic features in the cardiac type of glycogen storage disease II. Eur
Heart J, 1983. 4(1): p. 41-3.
70. Lorber, A. and A.S. Luder, Very early presentation of Pompe’s disease and its cross-sectional echocardiographic
features. Int J Cardiol, 1987. 16(3): p. 311-4.
71. Seifert, B.L., et al., Development of obstruction to ventricular outfl ow and impairment of infl ow in glycogen
storage disease of the heart: serial echocardiographic studies from birth to death at 6 months. Am Heart J,
1992. 123(1): p. 239-42.
72. Shapir, Y. and N. Roguin, Echocardiographic fi ndings in Pompe’s disease with left ventricular obstruction. Clin
Cardiol, 1985. 8(3): p. 181-5.
73. Hwang, B., et al., Clinical analysis of fi ve infants with glycogen storage disease of the heart--Pompe’s disease.
Jpn Heart J, 1986. 27(1): p. 25-34.
74. Mancall, E.L., G.E. Aponte, and R.G. Berry, Pompe’s disease (diffuse glycogenosis) with neuronal storage. J
Neuropath Exp Neurol, 1965. 24: p. 85-96.
75. Cardiff, R.D., A histochemical and electron microscopic study of skeletal muscle in a case of Pompe’s disease
(glycogenosis II). Pediatrics, 1966. 37(2): p. 249-59.
76. Hug, G. and W.K. Schubert, Glycogenosis type II. Glycogen distribution in tissues. Arch Path, 1967. 84: p. 141-152.
77. Garancis, J.C., Type II Glycogenosis; Biochemical and electron microscopic study. Americ J Med, 1968. 44: p.
289-299.
78. Gambetti, P., S. DiMauro, and L. Baker, Nervous system in Pompe’s disease. Ultrastructure and biochemistry.
J Neuropathol Exp Neurol, 1971. 30(3): p. 412-30.
26